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We demonstrated a microfluidic device for rapidly generating
complex mixtures of 32 stock reagents in a 5-nl reactor. This
‘‘formulation chip’’ is fully automated and allows thousands of
experiments to be performed in a single day with minimal reagent
consumption. It was applied to systematically study the phase
behavior of the protein xylanase over a large and complex chemical
space. For each chemical formulation that demonstrated a pro-
nounced effect on solubility, the protein phase behavior was
completely mapped in the chip, generating a set of empirical phase
diagrams. This ab initio phase information was used to devise a
rational crystallization screen that resulted in 72-fold improvement
in successful crystallization hits compared with conventional
sparse matrix screens. This formulations tool allows a physics-
based approach to protein crystallization that may prove useful in
structural genomics efforts.
The application of x-ray crystallography to the determinationof protein structure with atomic resolution was a triumph of
structural biology in the 20th century. Since the first solution of
the structure of myoglobin in 1958 (1), 23,000 different
structures have been deposited in the Protein Data Bank, and
their role in relating structure to function in biology has been
profound. As structure determination efforts continue to move
past the most tractable crystallization targets (typically small
soluble proteins) and focus instead on more challenging mac-
romolecules, such as large protein complexes and membrane
proteins (2), the need to better understand and explore the
crystallization process has become urgent. That is because once
high-quality crystals are in hand, advances in x-ray sources,
computer codes, and related technology have made it relatively
straightforward to obtain the structure. Determining the appro-
priate crystallization conditions has become one of the most
significant remaining bottlenecks to structure determination (3).
Understanding the phase behavior of proteins is an essential
part of the crystallization process. The growth of crystals from
a protein solution requires the existence of a nontrivial phase
diagram, which allows the protein state to be manipulated
between at least two thermodynamic phases: soluble and pre-
cipitated. The processes of crystal nucleation and growth arise
on the boundary between these two phases and are governed by
subtle effects in physical chemistry. There are a variety of
schemes that manipulate the kinetics of the crystallization
process, and all take advantage of generic features of these phase
diagrams (4). However, in practice, the phase behavior of very
few proteins has been studied in detail (5–12), and solubility
information for a specific protein is rarely available for crystal-
lization and optimization experiments (13, 14).
Furthermore, it is often an arduous process to find the right
combination of chemicals that yields appropriate phase behavior
for a given protein. Every protein is different, and even a modest
subset of stock precipitating solutions comprises a vast chemical
phase space that must be explored. The large amounts of sample
required make systematic exploration by conventional tech-
niques infeasible, and screening is typically directed toward an
incomplete factorial or sparse-matrix approach, a brute-force
process requiring large numbers of experiments (15, 16). There
have been numerous attempts to rationalize this procedure, for
example, by using computational approaches to predict phase
behavior (17, 18) or by trying to correlate measurements of
osmotic second virial coefficients (19, 20) with crystallization
conditions. Practical limitations have thus far prevented these
techniques from being generally applicable.
Here we describe a microfluidic formulation device that
allows for the combinatorial mixing of 16 buffers and 16 pre-
cipitation agents with a purified protein sample. The ability of
the formulation chip to access a vast number of chemical
conditions and to accurately dispense and mix fluids on the
picoliter scale makes detailed characterization of macromole-
cule phase behavior both possible and practical. We used this
device to screen 4,300 different solubility conditions of the
model protein Endo-1,4--xylanase from Trichoderma reesei.
Xylanase is a 21-kDa member of the gluconase enzyme family.
For those conditions that exhibited nontrivial phase behavior
(i.e., precipitation), a full phase diagram was generated. From
this thorough characterization of the phase behavior, we de-
signed a rational crystallization screen for xylanase. Comparison
of this screen to four commercially available sparse matrix
screens showed an increase of nearly two orders of magnitude in
crystallization success and allowed new insight into the physics
of crystallization.
Materials and Methods
Sample Preparation and Crystallization Protocols. Endo-1,4--
xylanase (xylanase) from T. reesei (Hampton Research, River-
side, CA) was prepared in deionized water from stock (36 mg/ml
protein43% wt/vol glycerol0.18 M sodium/potassium phos-
phate, pH 7.0) by repeated buffer exchange at 4°C using a
centrifugal filter with a molecular mass cutoff of 10,000 Da
(Micron Separations, Westboro, MA). Protein concentration
was measured by absorption at 280 nm and adjusted to a stock
concentration of 120 mgml. Ten-microliter aliquots were flash
frozen in liquid nitrogen and stored at80°C. To avoid sample–
sample variations, a single sample preparation was used for all
solubility screening, phase-space mapping, and corresponding
crystallization experiments. Batch crystallization trials were
actively mixed by repeated aspiration and incubated under
paraffin oil. Crystallization trials were inspected daily for a
period of 2 weeks. Observed crystals were confirmed to be
protein crystals by staining (IZIT dye, Hampton Research) and
were recorded as crystallization hits.
Experimental Setup and Data Collection. Automation of metering,
mixing, and data acquisition allows for thousands of solubility
experiments to be executed without the need for user interven-
tion. In each solubility experiment, a unique mixture of the 32
reagents and the protein sample is produced in the chip; details
of chip fabrication are in Supporting Text, which is published as
supporting information on the PNAS web site. All device control
and data acquisition were implemented by using a custom
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software driver developed in LABVIEW (National Instruments,
Austin, TX). Mixing recipes were generated by using a spread-
sheet program and translated into valve actuation sequences by
the software driver. Off-chip solenoid valves (Fluidigm, South
San Francisco, CA), controlled by using a digital input–output
card (DIO-32HS; National Instruments), were used to generate
square-wave pressure signals at the device control ports. A
frame-grabber card (Imagenation PXC200A, CyberOptics, Min-
neapolis) was used to automate image acquisition from a charge-
coupled device camera.
Absorption and Precipitation Measurements. Absorption measure-
ments were taken to determine the concentration of bromophe-
nol blue sodium salt (absorption peak at 590 nm) in the mixing
ring. A 9-m-high segment of the mixing ring (300  80 m)
having rectangular cross section was illuminated with a 590-nm
diode (AND180HYP; Newark Electronics, Chicago) and imaged
through a stereoscope (SMZ 1500; Nikon) onto a charge-
coupled device camera. Pixel intensities were averaged and
compared with an identical adjacent reference channel contain-
ing the undiluted dye (2 mM bromophenol blue sodium salt100
mM TrisHCl, pH 8.0). In some experiments, glycerol was added
to the injected dye to vary the viscosity. Dye concentrations were
determined by using the Beer–Lambert relation and used to
calculate the injected volume.
Precipitation of the protein was automatically detected by
imaging a portion of the mixing ring, calculating the standard
deviation of the pixel intensities, and comparing this value to the
background (no protein added). To ensure even illumination,
images were taken at112 magnification at a 9-m-high section
of the mixing ring having a rectangular cross section.
Positive-Displacement Crossinjection Metering. The metering
scheme allows for sequential injection of precise sample aliquots
from a single microfluidic channel into an array of reaction
chambers through a positive displacement crossinjection (PCI)
junction. The PCI junction is formed by the combination of a
three-valve peristaltic pump (21) and a four-port crossinjection
junction with integrated valves on each port (Fig. 1A). At each
junction, two sets of valves are actuated to direct the flow either
horizontally or vertically. To execute the metering task, the flow
is switched vertically through the junction, charging the cross-
injector with the sample fluid (Fig. 1B). The flow is then directed
horizontally through the junction, and the three valves forming
the peristaltic pump are actuated in a five-state sequence to
advance the fluid in the horizontal direction (Fig. 1C). Each
cycle of the peristaltic pump injects a well defined volume of
sample (80 pl), determined by the dead volume under the
middle valve of the peristaltic pump. The deflection of the valve
membranes when not actuated is determined by the pressure
difference across the membrane. The volume injected during
each cycle therefore may be tuned continuously, allowing for
variable positive displacement metering. By repeating the injec-
tion sequence, the volume of injected solution may be increased
in 80-pl increments, allowing for the dynamic quantized control
of the final downstream sample concentration.
The active region of the microfluidic formulation chip that
implements this scheme and allows for the arbitrary combina-
torial mixing of 16 stock reagents into one of 16 buffer solutions
is shown in Fig. 2A. Two 16-solution multiplexer arrays, actuated
by eight control lines, allow for the selection of buffers (Fig. 2A
Left) and reagents (bottom, Fig. 2 A). A PCI junction, formed by
a three-valve peristaltic injection pump (red) and crossinjection
valves (center green), dispenses directly into a 5-nl ring reactor.
Once the reactor has been flushed, a reagent line is selected, and
the crossinjection sequence is executed. The extended split
channel region increases the volume of the crossinjection junc-
tion, thereby allowing for up to 15 injections between flushing
steps. The maximum number of consecutive injections that may
be executed before the junction needs to be refreshed depends
on the Taylor dispersion (22) of the injected fluid as it is pumped
down the channel and is therefore a function of the viscosity. Fig.
2B shows the injection of four slugs, each having a volume of 80
pl, into the ring reactor. Arbitrary combinations of 16 reagents
may be produced in the reactor by sequential f lushing and
injection steps. Fig. 2C shows a color gradient formed from
injections of water and blue, green, yellow, and red dyes. In
screening applications that require the interrogation of a pre-
cious sample against many premixed reagent formulations, the
crossinjection flushing step is wasteful and is circumvented by
the addition of a separate sample injection site (Fig. 2D). After
the ring is filled with the desired reagents, they are mixed by
Fig. 1. PCI for robust and programmable high-precision dispensing on chip.
These schematic diagrams illustrate the PCI method. (A) A four-port PCI
junction. The split-channel architecture creates a large-volume injector re-
gion, thereby allowing for an increased number of injections before recharg-
ing. Channelsfluids are indicated in blue; valves are red. (B) Charging of the
injector region of the PCI junction. Junction valves are actuated to direct the
flow vertically through the junction, filling the injector region with orange
fluid. (C) Precise positive displacement metering by actuation of peristaltic
pump. A peristaltic pump is created by three consecutive valves; the pumping
sequence is shown. Pumping the blue fluid injects a metered volume of the
orange fluid into the next section of the chip (not shown). (D) The PCI junction
is sequentially charged with different solutions to create complex multicom-
ponent mixtures; in this case, the second injection is with a green fluid.
Fig. 2. Combinatorial mixing using a microfluidic formulator. These optical
micrographs show the manipulation of food dyes with the formulator chip. In
all images, the diameter of the mixing ring is 1.5 mm. (A) Integration of
multiplexer (dark blue), peristaltic pumps (red), rotary mixer (yellow), and PCI
junction (center, green) components for on-chip combinatorial formulation.
(B) Injection of250 pl (four injection cycles) of blue dye into rotary mixer. (C)
Color gradient formed by consecutive injections into mixing ring (eight injec-
tions blue, eight injections green, eight injections yellow, and eight injections
red). (D) Pumping around ring for 3 sec results in complete mixing of dye. Blue
dye is then added to mixture through sample injection inlet (bottom right).
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actuating a rotary peristaltic pump (23). The on-chip peristaltic
pumps were pneumatically actuated at 100 Hz, resulting in a
maximum flow velocity of 2 cmsec. At these flow rates,
complete mixing of aqueous reagents was achieved in 3 sec,
and solutions with viscosities of100 cP (1 P 0.1 Pasec) were
mixed in 6 sec. A real-time video illustrating the mixing and
metering process is included as Movie 1, which is published as
supporting information on the PNAS web site.
Device Characterization. The precision of metering was evaluated
by injecting variable amounts of dye (bromophenol blue sodium
salt; Sigma) into a reactor, mixing, and performing absorption
measurements. A set of 900 sequential titration experiments
(Fig. 3A) shows the metering to be both precise and reproduc-
ible, with a slope of 83.4 pl per injection cycle and a coefficient
of correlation of 0.996. The standard deviation of the injected
slug volume was determined to be 0.6 pl. Although positive
displacement metering ensures that the injected volume is robust
to changes in the fluid viscosity, the viscosity of the working fluid
does reduce the bandwidth of the injector. It was found that for
a solution having a viscosity of 400 cP, the frequency response
of the injector began to roll off at 10 Hz. When operating at an
injection frequency of 5 Hz, all solutions having viscosities400
cP produced equal injection volumes. Because the metering
mechanism is completely mechanical, there is no dependence on
the pH or ionic strength of the injected fluid. Additionally,
because the fluid is not dispensed from the chip, there is no
phase interface and therefore little dependence on surface
tension. The metering technique is therefore truly robust to the
physical properties of the injected fluid. Titration experiments
with fluids of varying glycerol concentration show the injection
volume to vary by 5% over a viscosity range of 1–400 cP
without modification to the injection sequence (Fig. 3B).
Results and Discussion
Although small-scale characterization of protein solubility by a
precrystallization solubility assay has been reported (15, 24, 25),
this technique has not been widely adopted, because the large
required sample volumes make it unsuitable for targets that
cannot be expressed and purified in large quantities. Microfab-
ricated dispensers have been used to reduce sample consumption
in cases where the sequential addition of reagents to a levitated
drop of microliter volume is sufficient to explore a restricted
chemical space (25). Although microfluidic devices have been
previously used to screen crystallization conditions using free
interface diffusion (19) and microbatch formats (20), they have
not been applied to systematically measure phase behavior
(26, 27).
Thorough characterization of protein solubility behavior requires
accessing a vast chemical space through the combinatorial mixing
of a limited number of stock reagents. The conventional reagents
used in crystallization exhibit a large variation in physical proper-
ties, such as viscosity, surface tension, ionic strength, and pH. This
variation presents a formidable challenge for fluid-handling systems
that must allow for arbitrary fluid combinations and proportioning.
We developed a PCI metering method that overcomes this obstacle,
allowing for variable dispensing to be dynamically programmed by
the user in 80-pl increments with5% variation over a broad range
of fluid properties. By combining this method with microfluidic
mixing (23) and multiplexing elements (28), large-scale combina-
torial screening has been achieved on chip for the first time. The
flexibility, precision, and small volume requirements of this device
make feasible the systematic mapping of crystallization phase space.
To demonstrate the utility of ab initio protein solubility
characterization, we used the formulator chip to exhaustively
explore the solubility behavior of a commercially available
crystallization standard, Endo-1,4--xylanase (xylanase) from T.
reesei (Hampton Research) (29, 30). Trial solutions were imaged
in the chip’s reactor ring, and the standard deviation of the
intensity of the imaged pixels was used as a metric of precipi-
tation; this allowed for distinction between precipitated and
soluble conditions and provided a rough quantitative measure of
the degree of precipitation. Beyond the precipitation limit, the
pixel standard deviation increases linearly with the protein
concentration and therefore is proportional to the concentration
of precipitated protein present in the solution (Fig. 4A). A video
of on-chip protein titration and precipitation is included as
Movie 2, which is published as supporting information on the
PNAS web site.
A coarse search of solubility space was performed initially, in
which the protein sample was mixed with a large number of
chemical formulations to identify conditions that produce non-
trivial phase behavior. This generates a solubility fingerprint of the
crystallization target in which each precipitation peak indicates a
chemical formulation that exerts a pronounced effect on solubility.
Fingerprints were generated for xylanase in four independent runs,
each of which consists of 4,000 titration experiments (Fig. 4B).
These fingerprints are highly reproducible and are characteristic of
the protein studied. For example, although sodium chloride is a
strong precipitating agent for chicken egg white lysozyme, it does
not produce a precipitation peak in the solubility fingerprint of
xylanase over the pH range studied.
Each solubility fingerprint was generated over a period of 20 h
and consumed 8 l of protein sample. Chemical formulations
were created by flushing the ring with one of 16 buffers, injecting
a precipitating agent (salt or polymer), diluting the ring with
water, and then mixing. Protein sample was then introduced at
a variety of concentrations and mixed before data acquisition.
When a polymer was used as the major precipitating agent, a
small amount of salt was also introduced as an additive. Exper-
iments in Fig. 4B were grouped by the identity of the major
precipitating agent so that each peak represents the effect of this
reagent over a range of pH values and concentrations. The large
width of these peaks indicates a high level of experimental
redundancy, suggesting that a more efficient search could be
conducted using fewer related chemical conditions.
The solubility fingerprint of xylanase reveals five salts
(sodium citrate, dipotassium phosphate, ammonium sulfate,
and sodiumpotassium tartrate) as likely crystallizing agents.
A high molecular-weight polymer (polyethylene glycol 8000) in
combination with various salt additives was also identified to
be a strong precipitating agent at high pH values. The high
isoelectric point of xylanase suggests that the reduced effec-
tiveness of this precipitant at low pH values is due to two-body
Fig. 3. Precise and robust microfluidic metering. Absorption spectroscopy is
used to measure the replaced fraction of fluid in the ring reactor from PCI
injections. The total ring volume is nominally 5 nl. (A) Precision and reproduc-
ibility of PCI injections. Each of the nine clusters represents 100 identical
injection sequences; the standard deviation of the clusters corresponds to an
injection error of 0.6 pl. (B) Absorption measurements of four sets of 20
injection and mixing sequences show the metering to be robust to the viscosity
of the injected fluid. Fluids contain varying amounts of glycerol and have
viscosities ranging from 1 to 400 cP.







electrostatic repulsion. A smaller molecular-weight polymer
(polyethylene glycol 3350) was found to be a much weaker
precipitating agent and was not investigated further in phase-
space mapping experiments.
The formulator chip was then used to measure full-phase
diagrams for the 24 most promising precipitation conditions.
Each phase diagram consisted of a grid of 72 separate mixing
experiments over all accessible protein and precipitant concen-
trations. All 24 phase spaces were generated sequentially on a
single device by using 3 l of protein sample (100 nl per
phase space) and are included in Fig. 6, which is published as
supporting information on the PNAS web site. A comparison of
precipitation phase spaces measured for xylanase in chip (5-nl
reactions) and in microbatch format under paraffin oil (5-l
reactions) shows good agreement in detecting the precipitation
boundary (Fig. 4C). Because measurements of precipitation are
made immediately after mixing (within 3 sec), the locus of points
that separate the precipitated and soluble regions of the graph
generates a precipitation curve that is distinct from the thermo-
dynamic solubility curve.
Conditions that reside just below the precipitated region may
be in a metastable state conducive to crystallization, so that a
detailed knowledge of protein solubility behavior provides an
empirical basis for the design of maximum likelihood crystalli-
zation trials. The 24 phase spaces generated for xylanase were
used to rationally design an optimal crystallization screen con-
sisting of 48 reagents. The formulations and protein concentra-
tions used in the optimized screen are in Table 1, which is
published as supporting information on the PNAS web site. A
single-batch crystallization trial using the optimal screen was set
by combining relative amounts of protein and precipitant stock
so that the final condition was located on the boundary of the
precipitation region. The efficiency of this screen was evaluated
by comparison with standard commercially available sparse
matrix screens (Crystal Screens I and II, Hampton Research;
Wizards I and II; Emerald Biostructures, Bainbridge Island,
WA). Two batch crystallization trials of 48 unique conditions
were prepared for each of the four sparse matrix screens for a
total of 384 individual assays
A list of the successful conditions from the rationally designed
crystallization screen and from the sparse matrix screens is
provided as Table 2, which is published as supporting informa-
tion on the PNAS web site. Twenty-seven crystallization condi-
tions were observed in the optimal screen compared with a total
of three crystallization conditions in the eight standard sparse
matrix screens. The use of ab initio solubility information
therefore resulted in a 72-fold enrichment in crystallization
Fig. 5. Comparison of xylanase microbatch crystallization experiments using
an optimal crystallization screen based on solubility phase spaces to commer-
cially available sparse matrix screens. (A) Histogram showing number of
successful crystallization conditions identified with sparse matrix screens (each
at protein concentrations of 12 and 23 mgml) and optimal screen. (B) Polar-
ized micrograph of large single crystals grown directly from optimal screen
(16% polyethylene glycol 800065 mM sodium chloride65 mM TrisHCl, pH
8.242 mg/ml xylanase). (Bar, 200 m.) (C and D) Comparison of phase-space
behavior and crystallization variability of the original protein sample (C) and
the second protein sample (D) in microbatch format. Conditions that gave rise
to crystallization are shown as black triangles. Conditions that gave rise to
immediate precipitation are represented as overlaid red circles. Blue circles
represent conditions in which the protein was soluble and did not produce
crystals.
Fig. 4. Automated exploration of protein solubility using the microfluidic
formulator. (A) Precipitation measurements at varying concentrations of
xylanase in 0.6 M potassium phosphate with 0.1 M TrisHCl, pH 6.5. The
standard deviation of pixel intensities provides a quantitative metric of pro-
tein precipitation in the ring reactor. Below the precipitation limit, the stan-
dard deviation shows constant background level with low variation. Above 12
mgml, the solution is in the precipitation regime, and the pixel standard
deviation exhibits an approximately linear dependence on protein concen-
tration. All points represent the mean of five identical experiments, with error
bars indicating standard deviation of measurements. (B) Solubility finger-
prints of xylanase over4,300 chemical conditions. Each data series represents
a separate fingerprinting experiment using the same basis of chemical con-
ditions. The top solubility fingerprint (red) is generated by using a sample
having elevated protein concentration (90 mgml) and exhibits both higher
signal-to-noise ratio and additional peaks not present in the other data series
(70 mgml). The two center solubility fingerprints were generated sequen-
tially on a single device (first green, then blue) with the same loaded sample,
demonstrating the stability of the protein over the time of the experiment
(40 h). The bottom solubility fingerprint (pink) was generated on a separate
device by using the same protein sample as the blue fingerprint, showing
reproducibility across devices. (C) Comparison of xylanase phase mapping
done on chip and in microbatch experiments. Conditions that gave rise to
precipitation in microbatch format and in chip are represented by red squares
and overlaid yellow circles, respectively. Conditions that did not produce
precipitation in either format are shown as blue circles. (D) Reversibility of
precipitation and solubility hysteresis for lysozyme observed by outward and
return titrations from the origin. The red region shows the area of phase space
in which precipitation was observed in both outward and return titrations.
The yellow region is the area of hysteresis in which the protein was soluble for
the outward titrations but precipitated in the return titrations. The blue
region is the area in which the protein was soluble for both the outward and
return titrations.
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success (Fig. 5A). A surprising result was that xylanase crystals
were observed in the optimal screen for all of the major salt and
polymer precipitants identified in the solubility fingerprint. This
striking finding suggests that achieving optimal levels of super-
saturation is more important in the crystallization of xylanase
than is the broad sampling of chemical space. In cases such as
this, systematic screening for crystallization using a reduced
chemical space may prove more effective than sparse matrix
strategies. Additionally, crystallization conditions were identi-
fied in the rationally designed screen that gave large single
three-dimensional crystals suitable for diffraction studies with-
out further optimization (Fig. 5B). In contrast, only flat plate
clusters were observed in the standard sparse matrix screens.
To evaluate the influence of lot variability on these crystalli-
zation results, crystallization trials based on the optimal screen
were repeated by using a new protein sample obtained from the
same vendor and prepared identically as the original sample.
Fourteen of 17 polyethylene glycol conditions that gave crystals
in the original experiment were reproduced by using the second
sample, compared with 1 of 10 for the salt-based conditions. To
determine whether the variable crystallization behavior ob-
served in salt-based conditions was due to variations in phase-
space behavior, a complete phase space of one chemical formu-
lation (sodiumpotassium tartrate, TrisHCl, pH 8.5) was
measured in microbatch format for both samples (Fig. 5 C and
D). It was discovered that, although both samples exhibited
similar phase-space behavior, they produced different crystalli-
zation results. Eleven conditions produced crystals in the orig-
inal sample compared with only one successful condition in the
second sample. The reason for this difference in behavior is
unclear but may be due to variable degrees of proteolysis or trace
amounts of chemical contaminants introduced during purifica-
tion or concentration steps. It is interesting that some crystal-
lization conditions (e.g., those based on polyethylene glycol
8000) are more robust to batch-dependent perturbations than
others.
Another application of protein solubility phase-space map-
ping is in transporting successful crystallization conditions from
one experimental format to another. The successful crystalliza-
tion of a protein is determined both by the established thermo-
dynamic variables and the kinetic trajectory of an experiment.
For this reason, experiments conducted with different crystal-
lization kinetics (e.g., hanging-drop vapor diffusion, microbatch,
and free-interface diffusion) and the same precipitating agents
will not necessarily produce similar results. For example, the
hydroxylase domain of a cytochrome p450 alkaline hydroxylase
(Mutant 139–3 of BM-3) did not produce crystals in initial
hanging-drop trials but was found to crystallize readily by
microfluidic free interface diffusion (26) (1 part protein 20
mg/ml1 part 30% m/v polyethylene glycol 80000.2 M sodium
acetate0.1 M TrisHCl, pH 7.0). However, this condition was
unsuccessful when set in hanging-drop vapor diffusion format,
resulting only in amorphous precipitate. The microfluidic for-
mulator was used to generate a phase space at constant buffer
and salt concentration (100 mM TrisHCl, pH 7.3200 mM
sodium acetate) with polyethylene glycol concentration and
protein concentration as variables. Two hanging-drop experi-
ments were designed to equilibrate near the solubility limit
determined from the phase-space map. One condition (8 l of
35 mgml protein sample mixed with 6.7 l of 10% polyethylene
glycol100 mM sodium acetate50 mM TrisHCl, pH 7.3, and
equilibrated at 20°C against 1 mM 20% polyethylene glycol200
mM sodium acetate100 mM TrisHCl, pH 7.3) produced crys-
tals within 3 days. This success demonstrates the usefulness of
solubility mapping in transporting conditions across crystalliza-
tion formats.
Finally, we used the formulator to make a direct observation
of the supersaturation region of chicken egg white lysozyme.
The concentrations of salt and lysosyme were manipulated
while keeping the buffer concentration constant to evolve the
chemical state of the mixing ring radially out from the origin
and then back again. Measurements of precipitation were
taken at 1-min intervals. The addition of a family of such
radial titrations was used to generate two phase-space dia-
grams for chicken egg white lysosyme: one for the outward and
one for the return titrations (Fig. 4D). The first observation of
protein precipitation appears at higher salt and protein con-
centration during the outward trajectory than on the return
path, thereby exhibiting solubility hysteresis. The intersection
of the soluble region of the outward phase space with the
precipitated region of the return path phase space provides a
direct observation of a metastable regime in which the aggre-
gate phase is thermodynamically stable but not observed at
short times. The observation of the reversible formation of a
protein aggregate may be used to distinguish between dena-
tured and well folded protein aggregates. Additionally iden-
tified metastable regions in phase space provide likely candi-
dates for crystal seeding and growth experiments.
Conclusion
We have shown that complex sample processing at the nanoliter
scale allows for a practical implementation of automated protein
solubility characterization. Ab initio solubility information ob-
tained through systematic protein phase-space mapping provides
a physical basis for the design of optimal crystallization screens,
giving rise to dramatic enrichment in crystallization success. It
must be noted that chemical conditions and phase behavior are
not the only variables that can be adjusted in the search for good
crystals; it is often equally important to tune the properties of the
protein by creating point mutants with or truncated constructs.
However, the path to crystallization always includes extensive
chemical screening with precious protein sample, and for this
step it appears that microfluidic formulation devices can play an
important role. Beyond applications in protein crystallization,
the formulation capability of this device should find diverse
applications in areas such as combinatorial chemistry, chemical
synthesis, and cell culture studies.
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